Its approval for non-cirrhotic MASH with fibrosis not only broadens the clinical scope of GLP-1 receptor agonists but also marks a paradigm shift toward metabolic-targeted therapies in liver disease. The gene discussed is GLP1R; the disease is liver disorder.